drugset
drugset / Trial / NCT02079480

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

NCT02079480 ↗

Phase 1 Terminated 130 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-986090 in healthy subjects.

Timeline

Start
2014-05
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986090 Unknown 0.5 mg Subcutaneous
Subject BMS-986090 Unknown 3 mg Subcutaneous
Subject BMS-986090 Unknown 10 mg Subcutaneous
Subject BMS-986090 Unknown 30 mg Subcutaneous
Subject BMS-986090 Unknown 100 mg Subcutaneous
Subject BMS-986090 Unknown 150 mg Subcutaneous
Subject BMS-986090 Unknown 300 mg Subcutaneous
Subject BMS-986090 Unknown 750 mg Subcutaneous
Background keyhole limpet hemocyanin Vaccine 1 mg Intramuscular

Indications

No indication recorded.